House panel blames FDA for drug shortages

Share this article:
Darrell Issa
Darrell Issa

A new report from the House Committee on Oversight and Government Reform blames FDA for shortages of generic injectable medications.

Chairman Darrell Issa (R-CA) says a committee investigation learned that FDA regulatory activity has effectively shut down 30% of manufacturing capacity at four of the largest US producers of generic injectable drugs.

Issa says FDA commissioner Margaret Hamburg and the agency have failed to ensure that its enforcement methods avoid “unnecessary shortages.”

The report notes that between 2010 and 2011, there was a 156% increase in FDA Warning Letters. “Warning letters have resulted in companies agreeing to take manufacturing off-line to address FDA criticisms,” it says. “Bedford Laboratories, Hospira Pharmaceuticals, Sandoz Pharmaceuticals, and Teva Pharmaceuticals were producing nearly one billion units of generic injectable products per year. Facilities at these companies are currently operating at about 700 million units per year. This decrease is a massive reduction in the industries' capacity to supply the nation with injectable medications.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters